CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the
CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research
Funding will advance 3D lung cell culture models to accelerate drug discovery CN Bio, a leading developer of single and multi-organ
Flowing to the beat of your heart
How mimicking blood flow makes Organ-on-a-chip technology even more life-like With every beat of your heart, blood rushes through your body. Some
How a novel in vitro Liver-on-a-chip model of fatty liver disease is being used to help prevent a global healthcare crisis.
Obesity is a global epidemic. Up to a third of the USA’s adult population is now obese and worldwide, the prevalence of obesity has almost tripled
CN Bio’s PhysioMimix® technology receives FDA recognition
FDA publication demonstrates advantages of PhysioMimix® in drug safety and metabolism applications, over standard techniques Represents the first
Life in the fastlane
How a partnership between the FDA and Organ-on-a-chip developers has the potential to fast-track drug development From a small discovery in a research
CN Bio and the University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients
CN Bio’s Lung-on-a-Chip technology will enable research into therapies to prevent interstitial lung disease and long-term lung impairment, following
CN Bio to provide drug metabolism and safety toxicity testing services
Extended range of services supports accelerated drug discovery and development using predictive 3D Liver-on-Chip technology CN Bio, a leading 3D cell
CN Bio and Imperial College London Collaboration
CN Bio and Imperial College London collaborate to identify novel treatments for alcoholic hepatitis. CN Bio’s Liver-on-Chip technology to define